Arlington Trust’s Maravai LifeSciences MRVI Stock Holding History

Arlington Trust’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-109	Closed	-$714	–	739
2023 Q4	$714	Buy	+109	New	+$704	﹤0.01%	863

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arlington Trust's MRVI Position: Q1 2024 in Review

Arlington Trust sold out of Maravai LifeSciences (MRVI) in Q1 2024, closing a stake of 109 shares — an estimated $714 sold.

Arlington Trust first reported a position in MRVI in Q4 2023 and held it in 1 quarter. The position peaked at $714 in Q4 2023. 210 funds tracked by Wall St. Rank hold MRVI as of Q1 2024.

Arlington Trust reported no remaining Maravai LifeSciences position as of Q1 2024 after selling out during the quarter.
Arlington Trust sold 109 Maravai LifeSciences shares in Q1 2024, an estimated $714.
Arlington Trust first reported a position in Maravai LifeSciences in Q4 2023 and held it in 1 quarter.
Arlington Trust's Maravai LifeSciences position peaked at $714 in Q4 2023.
210 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2024.

Based on Arlington Trust's 13F filing for Q1 2024, filed 16 Apr 2024.